DITROPAN oxybutynin hydrochloride 5mg tablet Australia - English - Department of Health (Therapeutic Goods Administration)

ditropan oxybutynin hydrochloride 5mg tablet

sanofi-aventis australia pty ltd - oxybutynin hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; brilliant blue fcf aluminium lake; lactose; calcium stearate - treatment of detrusor over-activity where conservative measures have failed.

YAZ drospirenone 3mg / ethinylestradiol 20 micrograms (as betadex clathrate) tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

yaz drospirenone 3mg / ethinylestradiol 20 micrograms (as betadex clathrate) tablet blister pack

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

PETIBELLE ethinylestradiol 30 microgram/ drospirenone 3 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

petibelle ethinylestradiol 30 microgram/ drospirenone 3 mg film coated tablet blister pack

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

YASMIN ethinylestradiol 30 micrograms / drospirenone 3 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

yasmin ethinylestradiol 30 micrograms / drospirenone 3 mg film coated tablet blister pack

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

ISABELLE TABLETS 3 mg/30 micrograms drospirenone/ethinylestradiol 3 mg/30 micrograms tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

isabelle tablets 3 mg/30 micrograms drospirenone/ethinylestradiol 3 mg/30 micrograms tablet blister pack

lupin australia pty limited - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet - excipient ingredients: maize starch; magnesium stearate; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

BROOKLYNN drospirenone/ethinyloestradiol 3 mg/30 microgram tablet blister composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

brooklynn drospirenone/ethinyloestradiol 3 mg/30 microgram tablet blister composite pack

alphapharm pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 0.03 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; polacrilin potassium - drospirenone/ethinyloestradiol-alphapharm 3/30 is indicated for use as an oral contraceptive.

PREXUM COMBI LD 2.5/0.625 perindopril arginine 2.5mg / indapamide hemihydrate 0.625mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

prexum combi ld 2.5/0.625 perindopril arginine 2.5mg / indapamide hemihydrate 0.625mg film-coated tablet bottle

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 0.625 mg; perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; maltodextrin; magnesium stearate; colloidal anhydrous silica; macrogol 6000; lactose monohydrate; colour - treatment of hypertension.

COVERSYL PLUS 5/1.25 perindopril arginine 5mg and indapamide hemihydrate 1.25 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

coversyl plus 5/1.25 perindopril arginine 5mg and indapamide hemihydrate 1.25 mg film-coated tablet bottle

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; maltodextrin; sodium starch glycollate type a; colloidal anhydrous silica; lactose monohydrate; colour - treatment of hypertension. treatment should not be initiated with this combination.

COVERSYL PLUS LD 2.5/0.625 perindopril arginine 2.5 mg and indapamide hemihydrate 0.625 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

coversyl plus ld 2.5/0.625 perindopril arginine 2.5 mg and indapamide hemihydrate 0.625 mg film-coated tablet bottle

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg; indapamide hemihydrate, quantity: 0.625 mg - tablet, film coated - excipient ingredients: macrogol 6000; colloidal anhydrous silica; lactose monohydrate; maltodextrin; magnesium stearate; sodium starch glycollate type a; colour - treatment of hypertension.

PERINDO COMBI 4/1.25 tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

perindo combi 4/1.25 tablet blister pack

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: hydrophobic colloidal silica anhydrous; magnesium stearate; microcrystalline cellulose; lactose monohydrate - treatment of hypertension. treatment should not be initiated with this combination.